Over a third of oncology trials disrupted by COVID-19 resume: GlobalData

More than one third of oncology trials disrupted by COVID-19 are now back on track (37.8%)- according to the latest report from GlobalData. This marks the largest number of oncology trials resumed since the pandemic disruptions began earlier this year. Oncology trials were seriously impacted by the virus causing many to be paused or suspended. The new report shows that in spite of the continued spread of the virus organizations have been implementing a number of strategies to ensure vital oncology studies can get back on track. These measures include remote monitoring and reducing the number of hospital visits required by patients especially those receiving treatments with immunosuppressive effects. The report notes that while telemedicine has helped in resuming trials challenges remain in particular for oncology patients who need to be closely and carefully monitored. Read more here.

CONTACT

BD@CROMOSPHARMA.COM

To arrange an introductory meeting and find out how our experience can benefit your next clinical project.